IBB

Ishares Biotechnology ETF

-$170.3M

Net Activity

Institutions Holding

919

Popularity Rank

#507

Avg Weight

0.17%

Total Value

$6.9B

Ownership Trend

919 institutions currently hold IBB, with 328 net buyers and 385 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

385

Net Buying Institutions

328

Key Holders

View all 919 holding institutions

Quarterly Activity

Recent Activity

+$4.6B

Total Buy Value

$3.7B

Total Sell Value

New buy55
Trim288
Add273
Sold out97

328

Net Buyers

385

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding ISHARES BIOTECHNOLOGY ETF (IBB)?
Major stakeholders currently include Bank Of America CORP /de/ ($1.2B), Citigroup INC ($865.0M), Morgan Stanley ($468.3M). Based on the latest 13F filings, there are a total of 919 tracked investment funds and institutions maintaining positions in IBB.
What is the overall institutional sentiment toward IBB recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $170.3M, driven by 328 managers accumulating shares while 385 reduced their exposure.
Which institutions have been selling or reducing their IBB positions?
In the latest period, 288 funds trimmed their holdings, and 97 managers completely exited their positions. The aggregate reported sell value was $3.7B.
Are there any notable investors adding IBB to their portfolios?
Yes, buying activity remains notable. 55 institutions opened new positions in {ticker}, and 273 existing holders added to their shares. The total reported buy value for the quarter amounted to $4.6B.

Related Stocks